Literature DB >> 31662025

A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling.

Rosita R Asawa1, Alexey Zakharov1, Taylor Niehoff1, Ata Chitsaz1, Ajit Jadhav1, Mark J Henderson1, Anton Simeonov1, Natalia J Martinez1.   

Abstract

Histone deacetylases (HDACs) are epigenetic modulators linked to diseases including cancer and neurodegeneration. Given their therapeutic potential, highly sensitive biochemical and cell-based profiling technologies have been developed to discover small-molecule HDAC inhibitors. Ultimately, the therapeutic action of these inhibitors is dependent on a physical engagement with their intended targets in cellular and tissue environments. Confirming target engagement in the cellular environment is particularly relevant for HDACs since they function as part of cell type-specific multiprotein complexes. Here we implemented two recently developed high-throughput target engagement technologies, NanoBRET and SplitLuc CETSA, to profile 349 compounds in the Epigenetic-Focused collection for HDAC1 binding. We found that the two HDAC1 target engagement assays correlated well with each other and with orthogonal activity-based assays, in particular those carried out in cellular environments rather than with isolated HDAC proteins. The assays detected a majority of the previously described HDAC1 inhibitors in the collection and, importantly, triaged HDAC inhibitors known to target other HDACs.

Entities:  

Keywords:  HDAC1; NanoBRET; SplitLuc CETSA; epigenetic compound library; profiling; qHTS; target engagement

Mesh:

Substances:

Year:  2019        PMID: 31662025      PMCID: PMC7848789          DOI: 10.1177/2472555219883625

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  32 in total

1.  Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays.

Authors:  Shuguang Huang; Lei Pang
Journal:  Assay Drug Dev Technol       Date:  2011-11-08       Impact factor: 1.738

Review 2.  Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.

Authors:  Heba M Hesham; Deena S Lasheen; Khaled A M Abouzid
Journal:  Med Res Rev       Date:  2018-05-07       Impact factor: 12.944

3.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Authors:  James Inglese; Douglas S Auld; Ajit Jadhav; Ronald L Johnson; Anton Simeonov; Adam Yasgar; Wei Zheng; Christopher P Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

4.  Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.

Authors:  Marjorie Boissinot; Martyn Inman; Aiden Hempshall; Sally R James; Jason H Gill; Peter Selby; David T Bowen; Ronald Grigg; Peter N Cockerill
Journal:  Leuk Res       Date:  2012-07-20       Impact factor: 3.156

Review 5.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

6.  Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay.

Authors:  Chia-Wen Hsu; David Shou; Ruili Huang; Thai Khuc; Sheng Dai; Wei Zheng; Carleen Klumpp-Thomas; Menghang Xia
Journal:  J Biomol Screen       Date:  2016-02-08

7.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

Review 8.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

Review 9.  HDAC expression and clinical prognosis in human malignancies.

Authors:  Wilko Weichert
Journal:  Cancer Lett       Date:  2008-12-21       Impact factor: 8.679

10.  jvenn: an interactive Venn diagram viewer.

Authors:  Philippe Bardou; Jérôme Mariette; Frédéric Escudié; Christophe Djemiel; Christophe Klopp
Journal:  BMC Bioinformatics       Date:  2014-08-29       Impact factor: 3.169

View more
  2 in total

1.  Bright and stable luminescent probes for target engagement profiling in live cells.

Authors:  N Connor Payne; Alena S Kalyakina; Kritika Singh; Mark A Tye; Ralph Mazitschek
Journal:  Nat Chem Biol       Date:  2021-10-21       Impact factor: 15.040

2.  2,3-Dehydrokievitone combats methicillin-resistant Staphylococcus aureus infection by reducing alpha-hemolysin expression.

Authors:  Hangqian Yu; Jingyu Liu; Li Wang; Shuhan Guan; Yajing Jin; Jianze Zheng; Hua Xiang; Dacheng Wang; Dianfeng Liu
Journal:  Front Microbiol       Date:  2022-08-23       Impact factor: 6.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.